American Psychiatric Association Slammed by Disease Mongering Parody Featuring Instant Disease Generation Engine

The American Psychiatric Association is under fire today by an independent health news site’s launch of the “Disease Mongering Engine” – an online tool that allows users to instantly generate disorders, dysfunctions and syndromes that sound real, but aren’t. Available at www.NewsTarget.com, the Disease Mongering Engine was created by Mike Adams, a vocal critic of modern psychiatric medicine and its practice of labeling healthy people with fictitious diseases, then over-medicating them with patented pharmaceuticals.

“Modern psychiatry has lost its way and has now become a marketing branch of Big Pharma,” Adams said. “Convincing healthy people that they’re diseased, then harming them with unsafe chemical medications, is not a legitimate approach to health and healing.” Diseases ranging from ADHD to Social Anxiety Disorder were “invented” by drug companies and psychiatrists, Adams says, as a way to generate billions of dollars in profits by selling treatment drugs and services to people who don’t need them.

California claims drug giant bribed docs to prescribe

California has joined a whistleblower lawsuit that claims Bristol-Myers Squibb Co. bribed doctors to prescribe its drugs, costing insurers perhaps millions of dollars in the largest alleged health care fraud case ever handled by the state, Insurance Commissioner Dave Jones announced Friday. The suit claims company salespeople plied physicians with speaking fees, expensive meals, gifts and trips to induce or reward them for prescribing large amounts of its drugs, which were billed to private insurers.

For example, the company invited doctors to attend Los Angeles Lakers games at Staples Center and spent thousands of dollars on luxury suites, the suit claimed.
“Golf outings, basketball camps, samba lessons, you name it,” Jones said at a news conference. The lawsuit said the aim was to boost prescription levels for legally approved and so-called “off-label” uses of drugs ranging from the antipsychotic Abilify to the blood thinner Plavix.

Panel to Examine Murder and Suicide Associated With Antidepressants

On Saturday morning April 9th of this year, a panel discussion will be held for the public and professionals on the theme of “Psychiatric Drug Tragedies: Personal, Legal and Medical Perspectives.” The two-hour presentation focuses on suicide and murder potentially caused by antidepressant medications. It is part of the international Empathic Therapy Conference put on by the Center for the Study of Empathic Therapy, Education & Living (April 8-10, 2011 in Syracuse, New York).
A great deal is now known about suicide and violence in association with the newer antidepressants such as Prozac (fluoxetine), Paxil (paroxetine), Zoloft (sertraline), Luvox (fluvoxamine), Celexa (escitalopram), Lexapro (escitalopram), Cymbalta (duloxetine), Effexor (venlavaxine), Pristiq desvenlafaxine), and Wellbutrin (bupropion).

Psychiatric drug industry driven by wealth and stealth, not mental health

Drug company corporate websites tell us of their integrity and utmost commitment to people’s health and well-being. The American Psychiatric Association’s website begins with “Healthy Minds. Healthy Lives” and asserts the “highest ethical standards of professional conduct.” Yet a mountain of evidence points to an entirely different picture. Most recently, thirty-eight state attorneys won a $68.5 million settlement with pharmaceutical titan AstraZeneca for unlawful marketing of antipsychotic Seroquel for unapproved use. These states also charged this company with failing to disclose the drug’s harmful side effects and concealing negative information about its safety and efficacy. “The company’s illegal practices put our most vulnerable populations at risk, including children and older patients with dementia and other debilitating diseases,” states Illinois Attorney General. U.S. sales of Seroquel brought in $5.3 billion for AstraZeneca last year.

Psychiatry’s Billing Bible, the DSM: The Debate over Diagnosis

Expected to be published in May 2013, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) – the bible of the American Psychiatric Association – has created a firestorm of controversy in its suggested treatment of individuals who have gender identity issues.

According to the manual, an individual questioning gender identity and meeting certain criteria suffers from gender identity disorder, which is therefore considered a mental disorder. And the new edition, whose revisions have been in the works for more than a decade, is likely to once again disappoint the vocal community that has been arguing for years that being transgendered is not a mental illness.

SHARE YOUR STORY/COMMENT: